



Company Name: SymBio Pharmaceuticals Limited November 9, 2012

Securities Code: 4582

Representative: Representative Director

President and Chief Executive Officer

Fuminori Yoshida

Direct Managing Officer

Inquiries: Chief Financial Officer

Hiroki Maekawa

TEL +81(3)5472-1125

SymBio Announces Revised Financial Forecast

SymBio today announced a revision of its financial forecast for the fiscal year 2012, previously disclosed on February14, 2012, to reflect current business fundamentals.

(1) Financial Forecast for Fiscal 2012 (January 1, 2012 to December 31, 2012)

	Net Sales	Operating Profit	Ordinary Profit	Net Profit	Net Profit per
					Share
	In millions of yen				
Previous Forecast (A)	2,338	(1,625)	(1,652)	(1,656)	(86.56)
Revised Forecast (B)	1,966	(1,844)	(1,858)	(1,862)	(97.33)
Decrease (B-A)	(372)	(219)	(206)	(206)	_
Percentage Change (%)	(15.9)	_	_	_	_
(Reference)					
Financial results for the	1,882	(2,066)	(2,095)	(2,104)	(143.60)
previous year ended					
December, 2011					

(2) Rationale for revision

The sales forecast for FY2012 is expected to be 1,966 million yen, 372 million yen lower than budget. For SyB D-0701, our antiemetic patch, data analysis will not be completed until the first half of next year. Thus, there is no possibility of out-licensing product rights for SyB D-0701 this year, decreasing the sales forecast with no upfront revenue on contracts for SyB D-0701 and fluctuation in the number of vials per delivery for TREAKISYM®, our oncology product being marketed in Japan.

While the reduction in SG&A costs have exceeded expectations with the use of cost-saving measures, we expect to register 1,862 million yen as net loss due to lower sales.

*Any forward-looking statements in this material, including the forecast of financial results, are estimates based on information available at the time and certain assumptions that SymBio's management believes to be reasonable. Actual results may differ substantially from such forecasts due to various factors.